Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Immuron Limited ( (AU:IMC) ) is now available.
Immuron Limited announced a change in the director’s interest, with Paul Brennan acquiring 1,000,000 unlisted options, increasing his direct holdings to 2,000,000 options. This change was approved by shareholders during the company’s Annual General Meeting, potentially strengthening the alignment of the director’s interests with the company’s strategic goals.
More about Immuron Limited
Immuron Limited is a biopharmaceutical company focused on developing and commercializing oral immunotherapy products for the treatment of gut-mediated diseases. The company primarily targets the healthcare sector with its innovative solutions aimed at addressing gastrointestinal health issues.
Average Trading Volume: 538,302
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$17.23M
See more data about IMC stock on TipRanks’ Stock Analysis page.